Compare HTCR & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | GRDX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Japan | United Kingdom |
| Employees | N/A | 2 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.4M |
| IPO Year | 2022 | N/A |
| Metric | HTCR | GRDX |
|---|---|---|
| Price | $0.23 | $2.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 385.6K | 112.2K |
| Earning Date | 03-30-2026 | 04-08-2026 |
| Dividend Yield | ★ 56.77% | N/A |
| EPS Growth | ★ 66.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.22 | $1.92 |
| 52 Week High | $1.66 | $5.30 |
| Indicator | HTCR | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 39.20 |
| Support Level | $0.22 | $2.03 |
| Resistance Level | $0.30 | $2.84 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.50 | 12.20 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.